Rocket Lab’s Neutron launch delay caused a 27% selloff, with shares recovering slightly. Third-quarter revenue hit $155 million, 17 Electron contracts, and a $1 billion backlog. Analysts rate it a moderate buy with a high target price, indicating potential upside for investors. Despite the delay, Rocket Lab shows strong growth potential.

Rocket Lab, often likened to “SpaceX-lite,” focuses on small-satellite launches. The Neutron rocket was set to increase payload mass significantly. However, a delay to Q1 2026 impacted investor confidence. Rocket Lab’s third-quarter financials showed impressive 48% revenue growth, a $1.05 billion backlog, and new defense contracts with the U.S. Air Force.

Although the Neutron delay caused a stock drop, recovery is underway. Rocket Lab’s premium valuation at 36 times revenue may deter some investors. However, expectations of strong fourth-quarter revenue growth and a potential $10 billion market by 2030 present a compelling growth narrative. Analysts rate the stock a moderate buy with a high target price.

Rocket Lab’s delay presents a buying opportunity. The stock’s recovery from the selloff highlights strong growth potential. Third-quarter financials showed significant revenue growth and a substantial backlog, reinforcing the company’s promising trajectory. Despite short-term challenges, analysts remain bullish on Rocket Lab’s long-term prospects.

Read more at Yahoo Finance: 1 Growth Stock Down 27% to Buy Right Now